RxDoctor Payments Data

Christina Wood

Family · Callicoon, NYNPI 1346526498

Payments from drug & device makers

$2,597in general payments, 2019–2025

Across 145 payments — averaging $17.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$908
  • Novo Nordisk$386
  • GSK$331
  • AbbVie$313
  • Otsuka America Pharmaceutical, Inc.$232
  • Pfizer$126
  • plus $301 from 7 others

What the payments were for

  • Food & beverage$2,597100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,597 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$165,660
Medicare patients
445
Services billed
1,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$109,826
EliquisApixaban90$92,944
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$87,636
FarxigaDapagliflozin Propanediol99$85,561
JardianceEmpagliflozin58$56,100
MounjaroTirzepatide27$52,575
XareltoRivaroxaban33$38,636
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$33,916
TrulicityDulaglutide22$30,401
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$28,477
MyrbetriqMirabegron26$26,481
RybelsusSemaglutide17$24,840
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$20,345
Incruse ElliptaUmeclidinium Bromide24$12,561
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$9,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$386$134,66580 claims
AstraZenecaFarxiga, Breztri Aerosphere$908$119,477149 claims
GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Shingrix$331$109,141152 claims
PfizerEliquis$126$92,94490 claims
AbbVieSynthroid$313$3,11146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in Callicoon

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →